United States v. Glaxo Group Ltd.
Case Date: 07/22/1973
|
United States v. Glaxo Group Ltd.[1] is a 1973 decision of the U.S. Supreme Court in which the Court held that (1) when a patent is directly involved in an antitrust violation, the Government may challenge the validity of the patent;[2] and (2) ordinarily, in patent-antitrust cases, “[m]andatory selling on specified terms and compulsory patent licensing at reasonable charges are recognized antitrust remedies.”
|